Trial Profile
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs RG 7697 (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Roche
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 31 Dec 2015 Status changed from active, no longer recruiting to completed according ClinicalTrials.gov record.
- 06 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.